for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

BNTX.O

現在値

134.88USD

変化

1.28(+0.96%)

出来高

735,183

本日のレンジ

133.03

 - 

136.25

52週レンジ

117.08

 - 

374.58

∙ 約20分前の相場を表示しています。

適時開示

EMA CHMP Backs Authorising Additional Adapted Version Of Comirnaty In Vaccinated People

Sept 12 (Reuters) - European Medicines Agency::EMA ADAPTED VACCINE TARGETING BA.4 AND BA.5 OMICRON VARIANTS AND ORIGINAL SARS-COV-2 RECOMMENDED FOR APPROVAL.EMA: COMIRNATY ORIGINAL/OMICRON BA.4-5 IS FOR USE IN PEOPLE AGED 12-YRS& ABOVE WHO HAVE RECEIVED AT LEAST PRIMARY COURSE OF VACCINATION AGAINST COVID.EMA: CLINICAL STUDIES WITH COMIRNATY ORIGINAL/OMICRON BA.4-5 ARE ONGOING AND CHMP WILL RECEIVE EMERGING CLINICAL DATA AS THEY ARE BEING GENERATED.EMA SAYS CHMP OPINION ON COMIRNATY ORIGINAL/OMICRON BA.4-5 WILL NOW BE SENT TO EUROPEAN COMMISSION, WHICH WILL ADOPT A FINAL DECISION.EMA: CHMP CONCLUDED COMIRNATY ORIGINAL/OMICRON BA.4-5 EXPECTED TO BE MORE EFFECTIVE THAN COMIRNATY AT TRIGGERING IMMUNE RESPONSE AGAINST BA.4, BA.5 SUBVARIANTS.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;;)).

EMA Says Preliminary Data Indicate Adapted Vaccines Have Ability To Neutralise Omicron Subvariants

Sept 2 (Reuters) - :EMA SAYS PRELIMINARY DATA ALSO INDICATE ADAPTED VACCINES HAVE ABILITY TO NEUTRALISE OTHER OMICRON SUBVARIANTS, INCLUDING BA.2, BA2.75, AND BA.5.EMA SAYS CURRENTLY EVALUATING AN APPLICATION FOR A COMIRNATY VACCINE TARGETING ORIGINAL SARS-COV-2 AND OMICRON SUBVARIANTS BA.4/5 .EMA SAYS OUTCOME OF REVIEW OF APPLICATION FOR COMIRNATY VACCINE TARGETING ORIGINAL SARS-COV-2 AND OMICRON SUBVARIANTS BA.4/5. EXPECTED BY MID-SEPT.EMA: ON ADAPTED VACCINES SAYS "WE EXPECT TO RECEIVE AN APPLICATION FROM MODERNA FOR A BA.4/5 IN SEPTEMBER".

U.S. CDC Recommends The First Updated Covid-19 Booster - statement

Sept 1 (Reuters) - :U.S. CDC RECOMMENDS THE FIRST UPDATED COVID-19 BOOSTER.CDC RECOMMENDS THE FIRST UPDATED COVID-19 BOOSTER- STATEMENT.CDC DIRECTOR ENDORSED RECOMMENDATIONS FOR USE OF UPDATED COVID BOOSTERS FROM PFIZER-BIONTECH FOR PEOPLE AGES 12 YEARS AND OLDER - STATEMENT.CDC DIRECTOR ENDORSED RECOMMENDATIONS FOR USE OF UPDATED COVID BOOSTERS MODERNA FOR PEOPLE AGES 18 YEARS AND OLDER.Further company coverage: [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

CDC Says No Evidence Of An Increased Risk For Myocarditis Following Mrna Covid-19 Vaccination In Children Aged 6 Months–5 Years

BioNTech SE <22UAy.DE>::CDC SAYS NO EVIDENCE OF AN INCREASED RISK FOR MYOCARDITIS FOLLOWING MRNA COVID-19 VACCINATION IN CHILDREN AGED 6 MONTHS–5 YEARS.CDC SAYS THERE HAVE BEEN NO UNEXPECTED SAFETY ISSUES IN EITHER MRNA VACCINE IN KIDS 6 MONTHS TO 5 YEARS.CDC SAYS NO STATISTICAL SIGNAL FOR MYOCARDITIS TO DATE IN CHILDREN AGES 5–11 YEARS FOLLOWING 1ST MRNA COVID-19 BOOSTER.CDC SAYS EVIDENCE SUGGESTS AN INCREASED RISK FOR MYOCARDITIS FOLLOWING 1ST COVID-19 BOOSTER DOSE IN ADOLESCENT AND YOUNG ADULT MALES.

BioNTech says Pfizer-BioNTech Omicron Ba.4/Ba.5 Covid-19 Bivalent Vaccine Available To Ship Immediately

Aug 31 (Reuters) - BioNTech ::PFIZER AND BIONTECH GRANTED FDA EMERGENCY USE AUTHORIZATION OF OMICRON BA.4/BA.5-ADAPTED BIVALENT COVID-19 VACCINE BOOSTER FOR AGES 12 YEARS AND OLDER.BIONTECH SE - APPLICATION FOR AN OMICRON-ADAPTED BIVALENT VACCINE FOR CHILDREN 5 THROUGH 11 YEARS OF AGE IS PLANNED FOR SUBMISSION TO FDA IN EARLY OCTOBER.BIONTECH SE - PFIZER-BIONTECH OMICRON BA.4/BA.5 COVID-19 BIVALENT VACCINE AVAILABLE TO SHIP IMMEDIATELY.BIONTECH SE - COMPANIES ARE WORKING WITH FDA TO PREPARE AN APPLICATION FOR AN OMICRON-ADAPTED BIVALENT VACCINE IN CHILDREN 6 MONTHS THROUGH 4 YEARS OF AGE.BIONTECH SE - ORIGINAL PFIZER-BIONTECH COVID-19 VACCINE WILL REMAIN AVAILABLE AS A BOOSTER DOSE FOR CHILDREN 5 THROUGH 11 YEARS OF AGE.BIONTECH SE - WILL FILE A NEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR THE OMICRON-BA.4/BA.5 BIVALENT BOOSTER VACCINE.BIONTECH SE - WILL SUPPLY THE ORIGINAL AND BIVALENT VACCINES UNDER THEIR EXISTING SUPPLY AGREEMENT WITH THE U.S. GOVERNMENT.

Pfizer can ship 15 Mln doses of updated COVID boosters by Sept. 9

Aug 31 (Reuters) - Pfizer Inc <PFE.N>::Pfizer says has capacity to ship up to 15 million doses of new ba.4/ba.5 bivalent COVID-19 vaccine boosters by sept. 9th-spokesperson.Pfizer says has hundreds of millions of bivalent vaccine doses manufactured pending regulatory authorization.Further company coverage: PFE.N. (Reporting By Michael Erman). ((Michael.Erman@thomsonreuters.com;)).

FDA Authorizes Moderna, Pfizer-Biontech Bivalent Covid-19 Vaccines For Use As A Booster Dose

Aug 31 (Reuters) - FDA::FDA AUTHORIZES MODERNA, PFIZER-BIONTECH BIVALENT COVID-19VACCINES FOR USE AS A BOOSTER DOSE.FDA - MODERNA COVID-19 VACCINE, BIVALENT, IS AUTHORIZED FOR USE AS A SINGLE BOOSTER DOSE IN INDIVIDUALS 18 YEARS OF AGE AND OLDER.FDA SAYS PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, IS AUTHORIZED FOR USE AS A SINGLE BOOSTER DOSE IN INDIVIDUALS 12 YEARS OF AGE AND OLDER.FDA - PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, IS AUTHORIZED FOR USE AS A SINGLE BOOSTER DOSE IN INDIVIDUALS 12 YEARS OF AGE AND OLDER.FDA - WITH AUG 31 ST AUTHORIZATION, MONOVALENT MRNA COVID-19 VACCINES ARE NOT AUTHORIZED AS BOOSTER DOSES FOR INDIVIDUALS 12 YEARS OF AGE AND OLDER.FDA - REVISED EUA OF MODERNA COVID-19 VACCINE, PFIZER-BIONTECH COVID-19 VACCINE TO REMOVE USE OF MONOVALENT MODERNA FOR BOOSTER ADMINISTRATION FOR 18 YEARS AND OLDER.FDA - REVISED EUA OF PFIZER-BIONTECH COVID-19 VACCINE TO REMOVE USE OF PFIZER-BIONTECH COVID-19 VACCINES FOR BOOSTER ADMINISTRATION FOR 12 YEARS AND OLDER.Further company coverage: PFE.N. ((Reuters.Briefs@thomsonreuters.com;)).

EMA Says CHMP Started Evaluating An Application For Authorisation Of An Adapted Version Of Comirnaty

Aug 30 (Reuters) - European Medicines Agency::EMA: EMA'S CHMP STARTED EVALUATING AN APPLICATION FOR THE AUTHORISATION OF AN ADAPTED VERSION OF COMIRNATY: 30/08/2022.Further company coverage: PFE.N [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

Pfizer And Biontech Announce Updated Covid-19 Vaccine Data Supporting Efficacy In Children 6 Months Through 4 Years Of Age

Aug 23 (Reuters) - BIONTECH SE <22UAy.DE>::PFIZER AND BIONTECH ANNOUNCE UPDATED COVID-19 VACCINE DATA SUPPORTING EFFICACY IN CHILDREN 6 MONTHS THROUGH 4 YEARS OF AGE.PFIZER INC. (NYSE: PFE) AND BIONTECH SE (NASDAQ: BNTX) TODAY ANNOUNCED UPDATED EFFICACY RESULTS FROM A PHASE 2/3 TRIAL EVALUATING A THREE 3-ΜG DOSE SERIES OF PFIZER-BIONTECH COVID-19 VACCINE IN CHILDREN 6 MONTHS THROUGH 4 YEARS OF AGE, REINFORCING PREVIOUSLY REPORTED INTERIM VACCINE EFFICACY DATA COLLECTED IN MARCH AND APRIL 2022.

Pfizer And Biontech Announce Updated Covid-19 Vaccine Data Supporting Efficacy In Children 6 Months Through 4 Years Of Age

Aug 23 (Reuters) - Pfizer <PFE.N> ::PFIZER AND BIONTECH ANNOUNCE UPDATED COVID-19 VACCINE DATA SUPPORTING EFFICACY IN CHILDREN 6 MONTHS THROUGH 4 YEARS OF AGE.PFIZER - VACCINE EFFICACY REMAINED CONSISTENTLY WELL ABOVE 70% IN BOTH 6 THROUGH 23 MONTHS AND 2 THROUGH 4 YEARS AGE GROUPS.PFIZER - SEQUENCING OF OBSERVED COVID-19 CASES CONFIRMED MAJORITY WERE CAUSED BY OMICRON BA.2, BROADENING EVIDENCE FOR EFFICACY ACROSS COVID-19 VARIANTS.PFIZER - WORKING WITH FDA TO PREPARE EUA APPLICATION FOR OMICRON BA.4/BA.5-ADAPTED BIVALENT VACCINE IN CHILDREN 6 MONTHS THROUGH 11 YEARS OF AGE.PFIZER - MAJORITY OF ADVERSE EVENTS OBSERVED IN AGE GROUP 2-4 YEARS HAVE BEEN MILD OR MODERATE, WITH A SAFETY PROFILE SIMILAR TO PLACEBO.PFIZER - THREE 3-MICROGRAM DOSES OF PFIZER-BIONTECH COVID-19 VACCINE CONTINUE TO BE WELL-TOLERATED IN AGE GROUP 2 - 4 YEARS.Further company coverage: [22UAy.DE]. ((Reuters.Briefs@thomsonreuters.com;)).

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up